DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS 
This systematic review and meta-analysis synthesizes data from 9 randomized controlled trials (26,224 participants) comparing bleeding risks between therapeutic-dose NOACs and aspirin. The evidence certainty ranged from low to moderate, with wide confidence intervals that often included null effects, indicating some uncertainty in the findings despite the rigorous methodology.
Key Clinical Considerations
- Apixaban demonstrated comparable major bleeding rates to aspirin (RD: 0.0 percentage points [95% CI: -1.3 to 2.6]) and similar intracranial hemorrhage risk (RD: -0.2 percentage points [95% CI: -0.6 to 1.4]).
- Dabigatran showed no significant difference in major bleeding (RD: 0.5 percentage points [95% CI: -2.1 to 19.6]) or intracranial hemorrhage (RD: 0.0 percentage points [95% CI: -1.1 to 24.5]) compared to aspirin.
- Rivaroxaban was associated with higher rates of major bleeding (RD: 0.9 percentage points [95% CI: -0.1 to 3.7]) and intracranial hemorrhage (RD: 0.3 percentage points [95% CI: -0.1 to 79.7]) versus aspirin.
- All trials used aspirin as the antiplatelet comparator, limiting generalizability to other antiplatelet agents like clopidogrel or ticagrelor.
- The wide confidence intervals for all comparisons suggest imprecision in the estimates, warranting cautious interpretation despite the statistical findings.
Clinical Practice Impact
- When selecting anticoagulation therapy, clinicians should consider that apixaban and dabigatran appear to have bleeding risk profiles similar to aspirin, while rivaroxaban may carry higher bleeding risks.
- These differential safety profiles should factor into patient-specific risk stratification, particularly for those at elevated bleeding risk.
- Treatment decisions should balance the superior thromboembolic protection of NOACs against their specific bleeding risk profiles, with possible preference for apixaban or dabigatran when bleeding risk is a primary concern.
More on Anticoagulants